SCHEDULE: Armistice Capital Discloses 5.65% Stake in Orthofix Medical

Armistice Capital, LLC and Steven Boyd reported a 5.65% beneficial ownership stake in Orthofix Medical Inc., totaling 2,236,000 common shares.

Summary

• Armistice Capital, LLC and Steven Boyd, collectively referred to as the "Reporting Persons," have filed an Amendment No. 5 to Schedule 13G regarding their beneficial ownership in Orthofix Medical Inc.
• The Reporting Persons beneficially own an aggregate of 2,236,000 shares of Orthofix Medical Inc. common stock.
• This ownership represents 5.65% of the class of securities, based on 39,599,659 shares outstanding as of October 31, 2025, as reported in the Issuer's Form 10-Q filed on November 4, 2025.
• Armistice Capital, LLC, as the investment manager of Armistice Capital Master Fund Ltd., exercises shared voting and dispositive power over all 2,236,000 shares.
• Steven Boyd, as the managing member of Armistice Capital, may also be deemed to beneficially own these securities.
• The securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing the control of the issuer, other than activities solely in connection with a nomination under Rule 14a-11.

Sentiment

Score: 7

Explanation: The disclosure of a significant beneficial ownership stake by an institutional investor is generally viewed as a positive signal, indicating confidence in the company's value and prospects.

Positives

• A significant beneficial ownership stake of 5.65% by an institutional investor like Armistice Capital, LLC, can be interpreted by the market as a vote of confidence in Orthofix Medical Inc.'s future prospects.
• The acquisition of shares in the ordinary course of business suggests a long-term investment perspective rather than a short-term speculative position.

Future Outlook

This filing is a beneficial ownership report and does not contain forward-looking statements or guidance from Orthofix Medical Inc. or the reporting persons regarding the company's future performance.

Management Comments

• Steven Boyd, Managing Member of Armistice Capital, LLC, certified that the securities were acquired and are held in the ordinary course of business and not for the purpose of or with the effect of changing or influencing the control of the issuer, other than activities solely in connection with a nomination under Rule 14a-11.

Industry Context

This filing reflects an institutional investor's position in the medical device industry, indicating a specific firm's investment strategy rather than broader industry trends or competitive analysis.

Stakeholder Impact

• Shareholders may perceive the significant institutional investment as a positive indicator, potentially boosting investor confidence and demand for the stock.
• The statement that the holding is not for the purpose of changing or influencing control (other than potential nominations) suggests a passive investment approach, which may reassure existing management and board.

Key Dates

Keywords

Orthofix Medical Inc., Armistice Capital, Steven Boyd, Schedule 13G, beneficial ownership, common stock, institutional investment, medical devices